Bayer

Bayer AG, a German pharmaceutical preparation manufacturing company, reported total GHG emissions of approximately 11.89 billion kg CO2e in 2025. This includes about 1.89 billion kg CO2e from Scope 1, 900 million kg CO2e from Scope 2 (market-based), and 9.10 billion kg CO2e from Scope 3 emissions. In 2024, the company's total emissions were approximately 11.78 billion kg CO2e, comprising around 1.88 billion kg CO2e from Scope 1, 1.08 billion kg CO2e from Scope 2 (market-based), and 8.82 billion kg CO2e from Scope 3. Looking further back, in 2019, Bayer AG's total emissions stood at approximately 14.1 billion kg CO2e, with about 2.08 billion kg CO2e from Scope 1, 1.68 billion kg CO2e from Scope 2 (market-based), and 10.34 billion kg CO2e from Scope 3.

Bayer AG has set ambitious climate commitments, with a long-term goal of achieving net-zero greenhouse gas emissions across its entire value chain by 2050 or earlier, including Scope 1, 2, and 3 emissions. This net-zero target translates to a 90% absolute reduction in Scope 1, 2, and 3 GHG emissions from a 2019 base year, with remaining emissions to be offset through long-term carbon credits. This target was validated by the Science Based Targets initiative (SBTi) in 2024.

For near-term targets, Bayer AG is committed to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2029, against a 2019 base year. They also aim to reduce absolute Scope 3 GHG emissions by 25% within the same timeframe, covering categories such as purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, and business travel. Additionally, Bayer AG aims to achieve climate neutrality at all its own sites (Scope 1 and 2) by 2030, with a 42% reduction in Scope 1 and 2 emissions by 2029 compared to 2019. The company also aims to enable farming customers to reduce on-field GHG emissions per kilogram of crop produced by 30% by 2030.